



Corporate Headquarters
747 Third Ave., 14th Floor, New York, NY 10017



Name
Address
City, State Zip Code



Healthcasts

NOW AVAILABLE!

Earn your CME credits: In order to complete this course and earn your CME credits, you must complete the evaluation/post-test after the program.

OVERVIEW

Personalized Approaches to Sustained Biologic Remission in Crohn’s Disease:

Introduction: Mucosal Healing in Crohn’s Disease (CD)

Case 1: Assessing mucosa in mild to moderate CD patients

Case 2: Preventing relapse and maintaining mucosal health in a CD patient who recently underwent an ileocecectomy

Case 3: Assessment of mucosal healing in a CD patient with perianal disease as assessed by serial MRI

Case 4: Mucosal healing in a patient with severe CD being treated with biologic therapy

Sponsored by FACTORx and MedEd Consulting, Inc.
This activity is supported by independent educational grants from AbbVie, Prometheus, and UCB, Inc.

Crohn's disease is a chronic, inflammatory disorder that can become disabling over time. Because it is a lifelong disease, maintaining symptomatic control and attaining remission are critical to minimizing short- and long-term complications and improving outcomes and quality of life for patients. To help improve outcomes for patients with Crohn's disease, the concept of mucosal healing (also referred to as sustained biologic remission) has been proposed as a therapeutic end point to gauge if treatment has reduced the intestinal mucosal damage that frequently accompanies Crohn's disease. This video will provide guidance on the appropriate use of mucosal healing in clinical settings. It begins with an overview of the use of mucosal healing in Crohn's disease followed by a discussion of four case studies.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with CD.

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

- Discuss the clinical benefits of mucosal healing in patients with CD
- Design an effective treatment plan that maximizes the occurrence of mucosal healing in patients with CD
- Evaluate the clinical utility of colonoscopy, non-invasive imaging techniques, and biomarkers for the assessment of mucosal healing in patients with CD

PROGRAM CO-CHAIRS

David T. Rubin, MD, FACG, AGAF, FACP
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
The University of Chicago Medicine
Chicago, IL

David T. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of

the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.

Dr. Rubin is a Fellow of the American Gastroenterological Association, the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy, the American College of Physicians, and an active national member of the Crohn's & Colitis Foundation of America (CCFA). He is also on the Board of Trustees for the ACG. Dr. Rubin has received numerous awards and honors, including being chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator's Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCFA's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families.

Dr. Rubin is the editor of a bestselling book on inflammatory bowel disease (IBD) and an author or coauthor of many peer-reviewed articles on IBD, virtual colonoscopy, genetic testing in IBD, and cancer in IBD. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, and in print media. His principal

research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.

William J. Sandborn, MD, FACG
Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego and UC San Diego Health System
La Jolla, CA

William J. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 522 peer-reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 99. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.

FACULTY

Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, PA

Gary R. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. He is currently the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. His research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

Dr. Lichtenstein also has received numerous awards including the award for the top specialist in the University of Pennsylvania Health System—the Louis A. Duhring Award. He is the recipient of the Christina and Marie Lindback award, which is the top teaching award in the entire University of Pennsylvania. He received the Penn Pearls Award for medical school teaching as well as the Donald B. Martin Teaching Award for the Department of Medicine Housestaff. He is listed in "The Best Doctors in America" for Inflammatory Bowel Disease and was listed among the top Gastroenterologists in Philadelphia for the elderly and Top Gastroenterologists in Philadelphia (Special Focus: Inflammatory Bowel Disease) by *Philadelphia Magazine*.

Dr. Lichtenstein has served on the Editorial Board of the journals *Gastroenterology*, *American Journal of Gastroenterology*, *Inflammatory Bowel Diseases*, *World Journal of Gastroenterology*, and *Digestive Diseases and Sciences*. He also served as a writer and section editor of Selected Summaries in the journal *Gastroenterology* as well as the section editor of Print and Media Review in *Gastroenterology*. He is the Executive Editor of the journal *Gastroenterology and Hepatology*, and served as Associate Editor of *Therapeutic Advances in Gastroenterology*, *The Physician and Sports Medicine*, and *Clinical Investigation*. He also served as Editor-in-Chief of the *World Journal of Gastroenterology*. An invited lecturer at the local, national, and international levels, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles,

chapters, letters, and editorials, and has presented over 250 abstracts and edited 18 books. He has lectured at a national and an international level at over 300 invited conferences, symposia, and institutional grand rounds.

DISCLOSURE STATEMENTS

FACULTY FINANCIAL DISCLOSURE STATEMENTS

The planning committee and presenting faculty reported the following:

Dr. Rubin is a consultant for AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen, Prometheus Laboratories, Shire, Emmi, Telsar Pharmaceuticals, and Santauras/Salix. He has received grant support from AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Genentech, Prometheus Laboratories, and Shire.

Dr. Rubin is not a member of speaker bureaus or advisory boards.

He does not hold stock options in these companies.

Dr. Sandborn is a consultant for AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen, and Receptos. He has received grant support from AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen, and Receptos.

He does not hold stock options in these companies.

Dr. Sandborn is not a member of speaker bureaus or advisory boards.

Dr. Lichtenstein is a consultant for AbbVie, Actavis/Alaven,

Ferring, Hospira, Janssen/Orthobiotech, Luitpold/American Regent Pharmaceuticals, Prometheus, Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB Pharmaceuticals, and Up-To-Date. He has received grant support from Ferring, Janssen/Orthobiotech, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB Pharmaceuticals, and Warner Chilcotte. He has received honoraria from Clinical Advances in Gastroenterology, Gastroenterology and Hepatology, Ironwood, Luitpold/American Regent, McMahon Publishing, SLACK, Inc., Springer Science and Business Media, and Up-to-Date.

He does not hold stock options in these companies.

EDUCATION PARTNER FINANCIAL DISCLOSURE STATEMENTS

Faculty and staff involved in the planning and review of this activity have nothing to disclose.

Mahira Zec Bonomo, MBA has no financial relationships to disclose.

Daniel Duch, PhD has no financial relationships to disclose.

DISCLOSURE

As a provider accredited by the Accreditation Council for Continuing Medical Education's (ACCME), The University of Chicago Pritzker School of Medicine requires everyone who is in a position to control the content of an education

activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, which could create a conflict of interest.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

In compliance with the ACCME updated accreditation criteria, presentations of those with reported potential conflicts were reviewed prior to presentation.

DISCLAIMER

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.

ACCREDITATION AND CERTIFICATE INFORMATION

ACCREDITATION AND DESIGNATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of

The University of Chicago Pritzker School of Medicine, FACTORx, and MedEd Consulting. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing these online activities, participants may receive a certificate by receiving a score of 70% or higher on each CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of each activity. The estimated time to complete this activity is 60 minutes.

ACTIVITY TYPE: Video

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported by independent educational grants from AbbVie, Prometheus, and UCB, Inc.

RELEASE DATE: October 30, 2015

EXPIRATION DATE: October 30, 2016

REFERENCE LIST

(1) Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. *Am J Gastroenterol* 2009;104(2):465-483.

(2) Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010;105(3):501-523.

(3) Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. *Aliment Pharmacol Ther* 2007;26(7):987-1003.

(4) Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). *Inflamm Bowel Dis* 2006;12(7):543-550.

(5) Kappelman MD, Porter CQ, Galanko JA et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17(1):62-68.

(6) Kappelman MD, Rifas-Shiman SL, Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008;135(6):1907-1913.

(7) Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. *Gastroenterology* 1999;117(1):49-57.

(8) Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. *Ann Surg* 1991;214(3):230-238.

(9) Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterology* 1990;99(4):956-963.

(10) Colombel JF, Reinisch W, Mantzaris GJ et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis. *Aliment Pharmacol Ther* 2015;41(8):734-746.

(11) Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007;133(2):412-422.

(12) Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis* 2009;15(9):1295-1301.

(13) Baert F, Moortgat L, Van AG et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. *Gastroenterology* 2010;138(2):463-468.

(14) Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. *Gastroenterology* 2015;148(1):37-51.

(15) Waters HC, Vanderpoel JE, Nejadnik B et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. *J Med Econ* 2012;15(1):45-52.

(16) Baars BJ, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. *Inflamm Bowel Dis* 2011;17(1):42-48.

(17) Sandborn WJ, Hanauer S, Van AG et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. *J Crohns Colitis* 2014;8(9):927-935.

(18) Cheifetz AS, Melmed GY, Spiegel B et al. Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert panel, and patient focus groups. *Inflamm Bowel Dis* 2012.

(19) De CP, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: A systematic review. *Inflamm Bowel Dis* 2012.

(20) Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2014;12(6):978-985.

(21) Onali S, Calabrese E, Pallone F. Measuring disease activity in Crohn's disease. *Abdom Imaging* 2012.

(22) Rimola J, Ordas I, Rodriguez S et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. *Inflamm Bowel Dis* 2011;17(8):1759-1768.

(23) Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. *J Hepatol* 2003;39(3):389-396.

(24) Florie J, Horsthuis K, Hommes DW et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. *Clin Gastroenterol Hepatol* 2005;3(12):1221-1228.

(25) Feagan BG, Lemann M, Befrits R et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. *Inflamm Bowel Dis* 2012;18(1):152-160.

(26) Bojic D, Bojic B, Protic M, Smith K. Fecal calprotectin is a reliable surrogate marker of endoscopic and histologic mucosal healing in Crohn's disease and ulcerative colitis. *J Crohns Colitis* 2011;5:S34.

(27) Manosa M, Garcia Planella E, Gordillo J, Smith K. Usefulness of faecal calprotectin to detect postoperative endoscopic recurrence in Crohn's disease. *J Crohns Colitis* 2011;5:S51.

(28) Algaba A, Linares PM, Fernandez-Contreras ME, Smith K. Relation between endoscopic and histological activity of the intestinal inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors. *J Crohns Colitis* 2011;5:S32.

(29) Bouguen G, Sninsky C, Tang KL et al. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. *Inflamm Bowel Dis* 2015;21(3):606-614.

(30) Van AG, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. *Nat Rev Gastroenterol Hepatol* 2010;7(2):79-85.

(31) Schirbel A, Sturm A. Imaging in Inflammatory Bowel Disease: Mucosal healing in ulcerative colitis: relevance for clinical outcomes. *Curr Drug Targets* 2012.

(32) Ferrante M, Karmiris K, Newnham E et al. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. *J Crohns Colitis* 2012;6(1):116-131.

(33) Armuzzi A, Van AG, Reinisch W et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. *J Crohns Colitis* 2012;6(4):492-502.

(34) Datamonitor. R&D trends: inflammatory bowel disease, unmet needs fuel diverse pipeline. New York, NY: Datamonitor; 2011. Report No.: HC00078-001